According to market research, the Hypercoagulability Treatment industry will be worth US$ 670 million in 2023 and US$ 1,317.99 million by 2033, growing at a CAGR of 7% over the forecast period. The market increased at a 4% CAGR between 2018 and 2022.
For In-depth insights, Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16682
The market’s expansion can be linked to increased knowledge of hypercoagulability and its negative consequences, as well as an increase in the prevalence of illnesses that raise the risk of hypercoagulability. As a result, demand for treatment choices is increasing, which will likely promote the development of new and creative medicines in the future. Furthermore, the market is expected to expand due to the increasing prevalence of hypercoagulability and a greater emphasis on improving patient treatment outcomes.
Numerous startups are entering the market as a result of the industry’s positive growth outlook, such as Novela Neurotechnology, a US-based startup that has developed an AI-driven platform called Neureka to speed up drug discovery by decoding neurological activity in the brain.
Because of the region’s high prevalence of hypercoagulability, North America is predicted to have a considerable share of the market, accounting for roughly 40% of total market value over the forecast period. Furthermore, government initiatives and research collaborations are boosting market growth in North America. The Asia Pacific market is also primed for expansion, with an emphasis on point-of-care healthcare and an increase in the number of hospitals in India and China giving a promising worldwide market opportunity.
Avail Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16682
Key Takeaways from the Market Study
- The Hypercoagulability Treatment market increased at a 4% CAGR from 2018 to 2022.
- From 2023 to 2033, the global Hypercoagulability Treatment market is predicted to increase at a 7% CAGR.
- The Hypercoagulability Treatment Market is anticipated to reach US$ 1317.99 Million by 2033.
- Hospitals have the biggest market share, according to the FMI research.
- North America is anticipated to account for 40% of the Hypercoagulability Treatment market.
- The Asia Pacific market is expected to grow significantly throughout the forecast period, accounting for 20% of the total.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Hypercoagulability Treatment.” says an FMI analyst
Market Competition
Key players in the market include pharmaceutical companies such as Bristol-Myers Squibb, Pfizer, Sanofi, Johnson & Johnson and Roche along with the healthcare providers and technology companies among other global players.
- In May 2020, the US Food and Drug Administration (FDA) approved Qinlock (ripretinib) tablets as a fourth-line treatment option for advanced gastrointestinal stromal tumors (GIST). Qinlock is a kinase inhibitor and is indicated for patients who have received three or more prior kinase inhibitor treatments, including imatinib. The approval was based on results of a randomized, double-blind, placebo-controlled clinical trial that enrolled 129 patients with advanced GIST. The trial showed that progression-free survival (PFS) was longer in the group receiving Qinlock compared to the placebo group. Qinlock was administered once a day in 28-day cycles until disease progression or intolerable side effects. After disease progression, patients in the placebo group had the option to switch to Qinlock.
More Insights Available
North America dominates the hypercoagulability market due to the high prevalence of thrombophilia in the region, favorable reimbursement policies, and the presence of major market players. Europe is also a significant market for hypercoagulability, driven by the increasing awareness about the condition and the growing adoption of advanced diagnostic tests and personalized treatments.
Customization Available@ https://www.futuremarketinsights.com/customization-available/rep-gb-16682
Key Segments Profiled in the Hypercoagulability Treatment Industry Survey
Drugs:
- Heparin
- Warfarin
- Direct Thrombin Inhibitor
Route of Administration:
- Oral
- Injectable
End Users:
- Hospitals
- Speciality Centers
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
